February / March #6 : Blind to the Cost

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Dancer from the Dance

Building Blocks

The Color of Money

Black Tie Lies

Wilson Cruz Grows Up

KS

S.O.S.

POZ Legacy: Pedro Zamora

(Some) Republicans Get AIDS

In Their Own Good Times

Kissy-Kissy

POZ Legacy: David B. Feinberg

POZ Legacy: Roxy Ventola

POZ Legacy: Tom Villard

Cracking Up

Blind to the Cost

Talk Show

Through the Glass Darkly

You're a Sex Goddess

A Model of HIV Replication

Doctor injects himself with HIV+ blood



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

February / March 1995

Blind to the Cost

Oral ganciclovir to prevent CMV

Preliminary results of a recent study sponsored by Syntex Corporation show that preventative treatment with an oral formulation of ganciclovir reduces the incidence of cytomegalovirus (CMV) by about 50 percent among people with AIDS and may prolong their survival. Infection with CMV—a herpesvirus that is frequently present in people with HIV—most commonly strikes the eye, where it can cause blindness, the colon, where it can cause debilitating diarrhea and the esophagus. In the study of people with less than 50 CD4 cells (or less than 100 CD4 cells and a previous AIDS-defining infection), an interim analysis showed that 16 percent of those taking oral ganciclovir developed some CMV disease compared to 30 percent of those on placebo. Due to the significant benefit noted, an independent review board halted the trial and ganciclovir was offered to all participants.

Syntex, which was recently purchased by Hoffmann-La Roche, has an application before the Food and Drug Administration (FDA) to use oral ganciclovir as maintenance therapy for people who have already been treated for an episode of CMV retinitis. Once the oral formulation is approved for maintenance therapy, doctors could prescribe it for prophylaxis as well, but insurers usually will not reimburse patients for such "off-label" use of a drug. This is significant because CMV prophylaxis with the oral formulation of ganciclovir is expected to cost $24,000 a year. AIDS Alert reports that the high cost (and fear of creating resistance to the drug) recently kept officials at the Centers for Disease Control and Prevention (CDC) from recommending oral ganciclovir for prevention of CMV as part of new guidelines for prophylaxis against opportunistic infections. Instead they encourage people with AIDS to monitor any changes in their field of vision and see their ophthalmologists regularly.

Scroll down to comment on this story.





Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.